Paper366407
The role of cis-platinum in solid-tumor therapy.
Einhorn LH and 1 other. N Engl J Med, 1979. Cited by 186 papers, by iCite.
Cite this record
ConductScience Library. The role of cis-platinum in solid-tumor therapy. Papers, record 366407. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/366407
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics15
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Cisplatin | Major topic |
| Neoplasms | Major topic |
| Age Factors | |
| Antineoplastic Agents | |
| Drug Evaluation | |
| Drug Therapy, Combination | |
| Female | |
| Head and Neck Neoplasms | |
| Humans | |
| Infusions, Parenteral | |
| Injections, Intravenous | |
| Male | |
| Ovarian Neoplasms | |
| Testicular Neoplasms | |
| Urinary Bladder Neoplasms |
Source PubMed
Cited by32
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 186 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42606259 | Mechanochemical Sustainable Synthesis of Platinum(II) Complexes: Reactivity Inversion and Coordination Mode Control. | Inorg Chem | 2026 | https://conductscience.org/library/papers/42606259 | PubMed |
| 35528662 | The role of hollow magnetic nanoparticles in drug delivery. | RSC Adv | 2019 | https://conductscience.org/library/papers/35528662 | PubMed |
| 34948122 | New Synthetic Lethality Re-Sensitizing Platinum-Refractory Cancer Cells to Cisplatin In Vitro: The Rationale to Co-Use PARP and ATM Inhibitors. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/34948122 | PubMed |
| 33193881 | Design and biological evaluation of novel BF-30 analogs for the treatment of malignant melanoma. | J Cancer | 2020 | https://conductscience.org/library/papers/33193881 | PubMed |
| 31723194 | Serum D-serine accumulation after proximal renal tubular damage involves neutral amino acid transporter Asc-1. | Sci Rep | 2019 | https://conductscience.org/library/papers/31723194 | PubMed |
| 30733337 | Loss of the tumor suppressor BIN1 enables ATM Ser/Thr kinase activation by the nuclear protein E2F1 and renders cancer cells resistant to cisplatin. | J Biol Chem | 2019 | https://conductscience.org/library/papers/30733337 | PubMed |
| 29761244 | Copper-tolfenamic acid: evaluation of stability and anti-cancer activity. | Invest New Drugs | 2019 | https://conductscience.org/library/papers/29761244 | PubMed |
| 29177461 | Rigorous Clinical Trial Design in Public Health Emergencies Is Essential. | Clin Infect Dis | 2018 | https://conductscience.org/library/papers/29177461 | PubMed |
| 27350330 | Ethoxyquin provides neuroprotection against cisplatin-induced neurotoxicity. | Sci Rep | 2016 | https://conductscience.org/library/papers/27350330 | PubMed |
| 23695549 | Visualizing inhibition of nucleosome mobility and transcription by cisplatin-DNA interstrand crosslinks in live mammalian cells. | Cancer Res | 2013 | https://conductscience.org/library/papers/23695549 | PubMed |
| 23467445 | C609T Polymorphism of NADPH Quinone Oxidoreductase 1 Correlates Clinical Hematological Toxicities in Lung Cancer Patients Treated with Amrubicin. | Clin Med Insights Oncol | 2013 | https://conductscience.org/library/papers/23467445 | PubMed |
| 19629622 | Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats. | Clin Exp Nephrol | 2009 | https://conductscience.org/library/papers/19629622 | PubMed |
| 18542749 | Should my accountant sing La Traviata at the Met? | Can Urol Assoc J | 2008 | https://conductscience.org/library/papers/18542749 | PubMed |
| 8318783 | Experimental and clinical studies on the intraperitoneal administration of cis-diamminedichloroplatinum (II) for peritoneal carcinomatosis caused by gastric cancers. | Surg Today | 1993 | https://conductscience.org/library/papers/8318783 | PubMed |
| 8070221 | Pharmacokinetic drug interactions with anticancer drugs. | Clin Pharmacokinet | 1994 | https://conductscience.org/library/papers/8070221 | PubMed |
| 6890414 | Blood clearance of three radioactively labelled platinum complexes: cis-dichlorodiammine platinum II, cis, trans-dichlorodihydroxy-bis-(isopropylamine) platinum IV, and cis-dichloro-bis-cyclopropylamine platinum II, in patients with malignant disease. | Cancer Chemother Pharmacol | 1982 | https://conductscience.org/library/papers/6890414 | PubMed |
| 6687235 | Enhanced cis-platinum neurotoxicity in pediatric patients with brain tumors. | J Neurooncol | 1983 | https://conductscience.org/library/papers/6687235 | PubMed |
| 6391659 | Effect of cis-platinum on human blood monocyte function in vitro. | Cancer Immunol Immunother | 1984 | https://conductscience.org/library/papers/6391659 | PubMed |
| 6122510 | High-dose dexamethasone for prevention of cis-platin-induced vomiting. | Cancer Chemother Pharmacol | 1981 | https://conductscience.org/library/papers/6122510 | PubMed |
| 6115628 | Urinary gamma-glutamyl transferase as an indicator of acute nephrotoxicity in rats. | Arch Toxicol | 1981 | https://conductscience.org/library/papers/6115628 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/366407
GET https://conductscience.org/api/papers/v1/366407/cited_by?page=2